The report “Coagulation Factors 2011 - who does meet the market needs? A Pipeline Assessment, Market Survey and Corporate Benchmark Analysis” provides a description, evaluation and assessment of the recombinant coagulation factor R&D pipelines as of October 2011. The authors analyze and assess the target pipeline for each of the coagulation factors for haemophilia and work out the target profiles of development projects. A market research study was conducted to challenge industry's target profiles and evaluate the sensitivity for pricing.
The report is built upon primary and secondary search for information and use of a proprietary database and news portal. A market survey was conducted among haematologists from haemophilia care centers. In house analysts with experience in biopharmaceutical R&D and business development authored the report and analysed and assessed the findings.
Global sales of the five major recombinant products of coagulation factors VIII, IX and VIIa in 2010 were US$ 6.2 bln (with $ conversion rate October 19, 2010). The first Marketing Authorization Application for a novel recombinant coagulation factor has been submitted in the European Union and further novel wild-type and long-acting recombinant coagulation factors VIII, IX and VII are in advanced clinical stages with potential regulatory approvals within the next 2 to 4 years. Given the progress of the pipeline, a concentration process of players has started. First clinical data are available and will guide further definition of R&D in this field.
Table 9: Total Market Size (US$ mln) of Rec Coagulation Factors in Hemophilia
*, includes Coagil VII
Figure 17: Critical half-life value for long-acting Factor VIII
First clinical data of long-acting factor VIII products indicate that the half-life is only about 1.7 fold longer than that of wild-type factorVIII which could trranslate in one injection less per week, but not a once-weekly adminstration. Would this difference be suificient for you to switch from wild-type to this “long-acting” factor VIII?